{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Bladder+Urothelial+Carcinoma&page=4",
    "query": {
      "condition": "Recurrent Bladder Urothelial Carcinoma",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 89,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Bladder+Urothelial+Carcinoma&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Bladder+Urothelial+Carcinoma&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T21:56:45.610Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00006376",
      "title": "R115777 in Treating Patients With Advanced Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Transitional Cell Cancer of the Renal Pelvis and Ureter"
      ],
      "interventions": [
        {
          "name": "chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-03",
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-10-10T21:56:45.610Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Tampa, Florida",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006376"
    },
    {
      "nct_id": "NCT02202772",
      "title": "Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma of the Urinary Bladder"
      ],
      "interventions": [
        {
          "name": "Cabazitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Guarionex J. Decastro",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2014-12-01",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2025-02-24",
      "last_synced_at": "2026-10-10T21:56:45.610Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02202772"
    },
    {
      "nct_id": "NCT00014144",
      "title": "S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Urethral Cancer"
      ],
      "interventions": [
        {
          "name": "gefitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 31,
      "start_date": "2001-02",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2012-10-08",
      "last_synced_at": "2026-10-10T21:56:45.610Z",
      "location_count": 95,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00014144"
    },
    {
      "nct_id": "NCT06331299",
      "title": "A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer",
        "Urothelial Carcinoma",
        "Urothelial Carcinoma Bladder"
      ],
      "interventions": [
        {
          "name": "UGN-103",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UroGen Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2024-08-29",
      "completion_date": "2026-09",
      "has_results": true,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-10T21:56:45.610Z",
      "location_count": 17,
      "location_summary": "Loma Linda, California • San Diego, California • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Powder Springs",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06331299"
    },
    {
      "nct_id": "NCT00021099",
      "title": "Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Distal Urethral Cancer",
        "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Proximal Urethral Cancer",
        "Recurrent Bladder Cancer",
        "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Recurrent Urethral Cancer",
        "Regional Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Stage III Bladder Cancer",
        "Stage IV Bladder Cancer",
        "Transitional Cell Carcinoma of the Bladder",
        "Urethral Cancer Associated With Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "ixabepilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2001-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-24",
      "last_synced_at": "2026-10-10T21:56:45.610Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00021099"
    },
    {
      "nct_id": "NCT00035061",
      "title": "A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urologic Neoplasms",
        "Metastases, Neoplasm"
      ],
      "interventions": [
        {
          "name": "pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-07-19",
      "last_synced_at": "2026-10-10T21:56:45.610Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Palo Alto, California • Boca Raton, Florida + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00035061"
    },
    {
      "nct_id": "NCT02437370",
      "title": "Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter",
        "Recurrent Bladder Carcinoma",
        "Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter",
        "Regional Urothelial Carcinoma of the Renal Pelvis and Ureter",
        "Stage III Bladder Urothelial Carcinoma",
        "Stage III Urethral Cancer",
        "Stage IV Bladder Urothelial Carcinoma",
        "Stage IV Urethral Cancer",
        "Urethral Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2015-09-01",
      "completion_date": "2020-03-10",
      "has_results": false,
      "last_update_posted_date": "2022-10-18",
      "last_synced_at": "2026-10-10T21:56:45.610Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02437370"
    },
    {
      "nct_id": "NCT00003167",
      "title": "Gene Therapy in Treating Patients With Advanced Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Bladder Cancer",
        "Stage I Bladder Cancer",
        "Stage II Bladder Cancer",
        "Stage III Bladder Cancer",
        "Stage IV Bladder Cancer",
        "Transitional Cell Carcinoma of the Bladder"
      ],
      "interventions": [
        {
          "name": "Ad5CMV-p53 gene",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "1998-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-23",
      "last_synced_at": "2026-10-10T21:56:45.610Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003167"
    },
    {
      "nct_id": "NCT00003824",
      "title": "S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "cephalexin",
          "type": "DRUG"
        },
        {
          "name": "surgical procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Ciprofloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "1999-04",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2012-03-09",
      "last_synced_at": "2026-10-10T21:56:45.610Z",
      "location_count": 90,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003824"
    },
    {
      "nct_id": "NCT05375903",
      "title": "A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-muscle Invasive Bladder Cancer",
        "NMIBC",
        "Carcinoma in Situ of Bladder",
        "Bladder Cancer",
        "Urothelial Carcinoma Bladder",
        "Urothelial Carcinoma Recurrent"
      ],
      "interventions": [
        {
          "name": "UGN-301",
          "type": "DRUG"
        },
        {
          "name": "UGN-201",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UroGen Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2022-06-01",
      "completion_date": "2026-01-09",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-10-10T21:56:45.610Z",
      "location_count": 7,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05375903"
    }
  ]
}